Radioactive Iodine Uptake in Response to Recombinant Human Thyrotropin Stimulation for Thyroid Remnant Ablation in Patients with Differentiated Thyroid Cancer

Koutsikos John

doi:10.26717/bjstr.2019.20.003487

Abstract

Highlights

The vast majority of differentiated thyroid tumours arise from thyroid follicular epithelial cells; papillary cancer corresponds to approximately 85% of cases, whereas about 12% of tumours have follicular histology, including Hürthle cell carcinomas [1]
We aimed to investigate the presence of variations in radioactive iodine uptake (RAIU) measurements after either rhTSH preparation or Thyroid hormone withdrawal (THW) in differentiated thyroid cancer (DTC) patients referred for thyroid remnant (TR) ablation, and to examine whether these potential discrepancies could influence the efficacy of TR ablation
radioactive iodine (RAI) ablation continues to have an important role in the management of DTC patients since TT remains the primary therapeutic option for patients suffering from DTC in many countries, in those where specialized thyroid cancer services are rare

Summary

Introduction

The vast majority of differentiated thyroid tumours arise from thyroid follicular epithelial cells; papillary cancer corresponds to approximately 85% of cases, whereas about 12% of tumours have follicular histology, including Hürthle cell carcinomas [1]. Total thyroidectomy (TT) has been indicated as the primary surgical treatment option for most differentiated thyroid lesions >1cm, independently of the presence of loco-regional or distant metastases [3]. When performing TT, the surgeon aims to remove as much thyroid tissue within the operative bed as possible. Complete thyroid tissue removal is demonstrated based on a negative post-operative whole-body scan (TxWBS), radioactive iodine uptake (RAIU)

Objectives

Methods

Results

Discussion

Conclusion